全文获取类型
收费全文 | 13390篇 |
免费 | 743篇 |
国内免费 | 105篇 |
专业分类
耳鼻咽喉 | 92篇 |
儿科学 | 360篇 |
妇产科学 | 111篇 |
基础医学 | 1605篇 |
口腔科学 | 353篇 |
临床医学 | 958篇 |
内科学 | 3722篇 |
皮肤病学 | 106篇 |
神经病学 | 925篇 |
特种医学 | 598篇 |
外科学 | 2268篇 |
综合类 | 65篇 |
预防医学 | 390篇 |
眼科学 | 137篇 |
药学 | 737篇 |
中国医学 | 21篇 |
肿瘤学 | 1790篇 |
出版年
2023年 | 175篇 |
2022年 | 314篇 |
2021年 | 494篇 |
2020年 | 237篇 |
2019年 | 299篇 |
2018年 | 427篇 |
2017年 | 287篇 |
2016年 | 310篇 |
2015年 | 307篇 |
2014年 | 414篇 |
2013年 | 482篇 |
2012年 | 797篇 |
2011年 | 841篇 |
2010年 | 496篇 |
2009年 | 402篇 |
2008年 | 713篇 |
2007年 | 730篇 |
2006年 | 718篇 |
2005年 | 692篇 |
2004年 | 679篇 |
2003年 | 639篇 |
2002年 | 577篇 |
2001年 | 246篇 |
2000年 | 250篇 |
1999年 | 264篇 |
1998年 | 165篇 |
1997年 | 143篇 |
1996年 | 138篇 |
1995年 | 114篇 |
1994年 | 98篇 |
1993年 | 85篇 |
1992年 | 194篇 |
1991年 | 185篇 |
1990年 | 133篇 |
1989年 | 143篇 |
1988年 | 130篇 |
1987年 | 116篇 |
1986年 | 120篇 |
1985年 | 110篇 |
1984年 | 64篇 |
1983年 | 61篇 |
1982年 | 35篇 |
1981年 | 32篇 |
1980年 | 25篇 |
1979年 | 42篇 |
1972年 | 25篇 |
1971年 | 39篇 |
1970年 | 28篇 |
1969年 | 30篇 |
1968年 | 25篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
101.
Komaki H Sugai K Sasaki M Hashimoto T Arai N Takada E Maehara T Shimizu H 《Epilepsia》1999,40(3):365-369
We report a surgically treated case of early infantile epileptic encephalopathy (EIEE) with suppression-bursts associated with focal cortical dysplasia. Tonic-clonic seizures followed by a series of spasms occurred about a hundred times a day at a few days of age. Interictal electroencephalogram (EEG) revealed a suppression-burst pattern that was predominant in the left hemisphere. Magnetic resonance imaging (MRI) suggested focal cortical dysplasia in the left prefrontal area. Combination therapies with antiepileptic treatments showed only partial efficacy. The patient underwent lesionectomy at age 4 months, after which he gradually showed psychomotor development and a decrease of spasms to 0-2 series daily. In cases of EIEE with focal cortical dysplasia, surgical treatment may have beneficial effects on both psychomotor development and seizure control. 相似文献
102.
103.
104.
105.
Endothelin antagonist treatment for successful liver transplantation from non-heart-beating donors 总被引:2,自引:0,他引:2
Fukunaga K Takada Y Taniguchi H Mei G Seino KI Yuzawa K Otsuka M Todoroki T Goto K Fukao K 《Transplantation》1999,67(2):328-332
BACKGROUND: With the shortage of cadaveric donors, non-heart-beating donors (NHBDs) are a potential source of liver allografts. However, warm ischemic injury in NHBDs seriously affects the viability of graft liver. Endothelin (ET)-1 has been reported to be involved in the hepatic microcirculatory disturbances after ischemia-reperfusion. METHODS: In a porcine orthotopic liver transplantation model, changes in the serum and liver tissue ET-1 concentration were measured and the effects of an ET receptor antagonist, TAK-044, were evaluated. After cardiac arrest of the donors, liver allografts were subjected to 90 min of warm ischemia, flushed, and preserved for 4 hr at 4 degrees C. The pigs were divided into two groups: a control group (no drug treatment) and a drug-treated group, in which donors and recipients were treated with TAK-044 (10 mg/kg body, drip intravenous injection). Both groups had six donor/recipient pairs. RESULTS: -The ET-1 concentration in the hepatic venous blood increased after reperfusion of the graft in the control group recipients. ET-1 in the graft liver significantly increased during the cold preservation period. TAK-044 treatment significantly increased recipient 7-day survival rate. After reperfusion of the graft, the concentrations of serum liver enzymes and arterial lactate in the drug-treated group were significantly lower than in the control group. The postoperative increase in portal venous pressure was significantly reduced in the drug-treated group. Measurements of liver enzymes in the washed-out preservation fluid at the time of graft rinsing indicated that TAK-044 treatment of the donors significantly suppressed liver enzyme release during ischemia. CONCLUSIONS: These findings indicate TAK-044 treatment has protective effects on postoperative function of hepatic allografts procured from NHBDs. 相似文献
106.
Total Esophagectomy versus Proximal Esophagectomy for Esophageal Cancer at the Cervicothoracic Junction 总被引:1,自引:0,他引:1
Fujita H Kakegawa T Yamana H Sueyoshi S Hikita S Mine T Tanaka Y Ishikawa H Shirouzu K Mori K Inoue Y Tanabe HY Kiyokawa K Tai Y Inutsuka H 《World journal of surgery》1999,23(5):486-491
To investigate the adequate extent of esophagectomy and lymphadenectomy for an esophageal cancer localized at the cervicothoracic
junction, the mortality and morbidity rates, survival rates, and patterns of recurrence were retrospectively analyzed in two
groups—14 patients who underwent total esophagectomy with or without laryngectomy and 15 patients who underwent proximal esophagectomy
with or without laryngectomy—at Kurume University Hospital from 1981 to 1996. Proximal esophagectomy with or without laryngectomy
resulted in a lower hospital mortality rate and better overall survival for patients who underwent curative esophagectomy
compared with total esophagectomy with or without laryngectomy. Multivariate analysis indicated that the extent of esophagectomy
(total esophagectomy versus proximal esophagectomy) was not a prognostic factor. The incidence of recurrence was not different
between the two groups. Lymph node metastasis or recurrence from such esophageal cancers was localized to the neck and upper
mediastinum. For an esophageal cancer localized at the cervicothoracic junction, therefore, proximal esophagectomy with or
without laryngectomy and with cervical and upper mediastinal lymphadenectomy could be better indicated for preselected patients. 相似文献
107.
Takada J Stepanov VE Yefremov DP Shintani T Akiyama A Fukuda M Hoshi M 《Journal of radiation research》1999,40(3):223-228
A radiological survey around the site of Kraton-4, an underground nuclear explosion (Yield of 20 kt, depth of 560 m, 1978) in Sakha was carried out in March 1998. Gamma survey and in-situ spectroscopy on the ground exhibited quite normal levels: a dose rate of 0.022 microSv/h and Cs-137 surface contamination of less than 1.1 kBq/m2 around the hypocenter. The results suggested no remarkable leakage of radioactivity from the epicenter to the ground surface at least not for non-rare gas elements as of 1998. 相似文献
108.
Y Sakurai-Yamashita K Takada K Takemura K Yamashita A Enjoji T Kanematsu K Taniyama 《Japanese journal of pharmacology》1999,79(4):493-496
Ability of mosapride, a gastrokinetic agent, to bind to 5-HT4 receptor was examined in the stomach of human and guinea pig by in vitro receptor autoradiography. [125I]SB207710 binding sites were detected in the muscle layer including the myenteric plexus of the stomach from both humans and guinea pigs, although the binding was observed more clearly and densely in the stomach of guinea pigs than humans. Mosapride as well as SB204070 inhibited the binding of [125I]SB207710. Thus, mosapride possesses the ability to bind to 5-HT4 receptors of human stomach and may modulate the motility, as in the case of guinea pig stomach. 相似文献
109.
The interactions of four HIV-protease inhibitors, ritonavir (RIT), saquinavir (SAQ), indinavir (IND) and nelfinavir (NEL), were examined by in vitro metabolic studies using rat liver microsomal fractions. The substrate concentrations employed were 0.75 approximately 12 microM, and the inhibitor concentrations were 2.5 approximately 60 microM. The metabolic clearance rates of SAQ, NEL and IND as determined by V(max)/K(m) were 170.9+/-10.9, 126.0+/-4.4 and 73.0+/-2.0 microL/min/mg protein, respectively. RIT was a potent inhibitor of the other three protease inhibitors, and the inhibition constants (K(i)) were 1.64 microM for SAQ, 0.95 microM for IND and 1. 01 microM for NEL. NEL was the second strongest inhibitor with a K(i) for NEL inhibition of IND metabolism of 2.14 microM. IND was the third strongest inhibitor with K(i)s of 2.76 microM for inhibition of NEL and 3.55 microM for inhibition of SAQ. As SAQ has the highest metabolic clearance rate, the K(i) for the SAQ inhibition of IND metabolism was high, 9.50 microM. Based on these in vitro results, drug interactions between NEL and IND or RIT were studied after oral administration to rats where the dose of each drug was 20 mg/kg. The C(max) and AUC of NEL were increased 3.6- and 8.5-fold by the co-administration with RIT. However, in contrast to co-administration of NEL and RIT, the effect of IND on the pharmacokinetics of NEL was negligible and the t(1/2) of NEL was not significantly increased by IND. Therefore, the combination of NEL and IND is recommended as a combination therapy for AIDS patients. 相似文献
110.
Noriyuki Masuda Shunichi Negoro Kouji Takeda Nobuhide Takifuji Tomonori Hirashima Takashi Yana Noriaki Kurata Takashi Kuwabara Satoshi Kobayashi Shinzoh Kudoh Kaoru Matsui Minoru Takada Masahiro Fukuoka 《Investigational new drugs》1999,16(3):245-254
(E)-2-deoxy-2-(fluoromethylene)cytidine (FMdC), one of the most potent inhibitors of ribonucleoside diphosphate reductase, was selected for clinical development because of its novel mechanisms of action, and strong antitumor activity against experimental tumor models. This study was designed to determine the toxicities, maximum-tolerated dose (MTD), and pharmacokinetic profile of FMdC. FMdC was given orally for 5 consecutive days every 3 or 4 weeks in patients with advanced solid tumors. The starting dose was 8 mg/m2/day. Pharmacokinetic studies were carried out on days 1 through 5 of the first cycle. Ten patients with non-small cell lung cancer received 15 courses of FMdC at doses which were de-escalated from 8 mg/m2/day to 2 mg/m2/day because of unexpected severe toxicities at the starting dose level. Neutropenia was the dose-limiting toxicity. Thrombocytopenia and anemia were mild. Flu-like symptoms and fever were the common non-hematologic toxicities. The MTD was 4 mg/m2/day, since four of six patients developed grade 3–4 neutropenia. At the 4 mg/m2/day dose level, the mean terminal half-life, maximum plasma concentration (Cmax), plasma clearance, and mean residence time on day 1 were 3.20 h, 15.8 ng/ml, 2.91 l/h/kg, and 4.03 h, respectively. The recommended dose for phase II studies with this schedule is also 4 mg/m2/day for 5 days. Further investigations are necessary to establish optimal dosing schedules and routes for the administration of FMdC. 相似文献